HC Wainwright Has Positive Forecast for CorMedix Q4 Earnings

CorMedix Inc (NASDAQ:CRMD) – HC Wainwright raised their Q4 2025 earnings estimates for shares of CorMedix in a research report issued to clients and investors on Thursday, November 13th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of $0.94 per share for the quarter, up from their previous forecast of $0.90. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for CorMedix’s FY2029 earnings at $2.57 EPS.

CRMD has been the subject of several other reports. Weiss Ratings restated a “hold (c)” rating on shares of CorMedix in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of CorMedix from a “buy” rating to a “hold” rating in a research note on Saturday. D Boral Capital raised CorMedix from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Needham & Company LLC decreased their price objective on CorMedix from $20.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, JMP Securities reissued a “market outperform” rating and issued a $22.00 price objective on shares of CorMedix in a research note on Tuesday, September 9th. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, CorMedix has a consensus rating of “Buy” and an average price target of $18.33.

CorMedix Stock Performance

CRMD opened at $11.24 on Friday. CorMedix has a one year low of $5.60 and a one year high of $17.43. The company has a market capitalization of $880.54 million, a PE ratio of 14.99 and a beta of 1.80. The stock’s fifty day moving average is $11.39 and its 200-day moving average is $12.08.

CorMedix (NASDAQ:CRMD) last announced its earnings results on Wednesday, November 12th. The company reported $1.26 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.78. The business had revenue of $2.73 million during the quarter, compared to analysts’ expectations of $65.63 million. CorMedix had a net margin of 42.11% and a return on equity of 42.73%. The business’s revenue was up 810.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.05) earnings per share. CorMedix has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.

Insider Buying and Selling

In other news, COO Elizabeth Hurlburt sold 41,121 shares of CorMedix stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $13.08, for a total transaction of $537,862.68. Following the completion of the transaction, the chief operating officer directly owned 176,990 shares in the company, valued at approximately $2,315,029.20. The trade was a 18.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Joseph Todisco sold 50,000 shares of the company’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $13.00, for a total value of $650,000.00. Following the completion of the transaction, the chief executive officer directly owned 509,496 shares of the company’s stock, valued at approximately $6,623,448. The trade was a 8.94% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 163,997 shares of company stock worth $2,163,617. 3.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CorMedix

Large investors have recently bought and sold shares of the business. Teacher Retirement System of Texas bought a new position in CorMedix in the first quarter worth about $98,000. Bank of New York Mellon Corp lifted its stake in CorMedix by 10.4% during the first quarter. Bank of New York Mellon Corp now owns 143,238 shares of the company’s stock worth $882,000 after purchasing an additional 13,543 shares during the period. Arizona State Retirement System bought a new position in shares of CorMedix in the 1st quarter valued at about $107,000. Sigma Planning Corp grew its stake in shares of CorMedix by 7.8% during the 1st quarter. Sigma Planning Corp now owns 36,305 shares of the company’s stock worth $224,000 after acquiring an additional 2,612 shares in the last quarter. Finally, SBI Securities Co. Ltd. boosted its stake in shares of CorMedix by 699.7% in the first quarter. SBI Securities Co. Ltd. now owns 8,685 shares of the company’s stock valued at $54,000 after buying an additional 7,599 shares during the period. 34.18% of the stock is currently owned by institutional investors.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.